Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm PII Alzheimer’s Study Gets Underway in Europe
December 26, 2019
- Opdivo/Yervoy Combo Filed for Frontline NSCLC in Japan
December 26, 2019
- Kyowa Hakko Bio Hit with 18-Day Biz Suspension over GMP Failings
December 25, 2019
- 15% Share Eyed for Jointly Developed Symbicort Generics, Toa Set to Push Uptake with Support App
December 25, 2019
- Gilead Japan Hooks Up with Arthritis-Savvy Eisai for JAK Inhibitor
December 25, 2019
- ASKA Files Uterine Fibroid Drug in Japan
December 25, 2019
- Renascience, ASKA Pair Up to Develop Pyridoxamine
December 25, 2019
- Sosei, Pfizer Nominate 3rd Development Candidate Compound
December 25, 2019
- Towa to Acquire Spanish Generic Player, Set to Venture into US/European Markets
December 24, 2019
- Eisai’s Insomnia Drug Grabs US Approval, Japan Nod Expected Soon
December 24, 2019
- US FDA Accepts Resubmission for Sunovion’s Parkinson’s Med
December 24, 2019
- Promethera to Launch Japan Trial of Cell Therapy Targeting ACLF by FY2021
December 24, 2019
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
December 24, 2019
- Sumitomo/Poxel Wraps Up Japan Pivotal Program for Imeglimin with Successful Long-Term Study
December 23, 2019
- Bayer, Santen Extend Eylea Tie-Up in Japan
December 23, 2019
- Daiichi Sankyo/Amgen’s Avastin Biosimilar Now Available
December 20, 2019
- Astellas/Seattle Genetics Nabs FDA OK for 1st-in-Class ADC
December 20, 2019
- Takahiko Iwaya to Take Over as Sanofi Japan President on Jan. 1
December 20, 2019
- Takecab Back on Top in Hospital Promotion Ranking in October: Impact Track
December 19, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…